Wei, Tuo http://orcid.org/0000-0002-2823-9721
Sun, Yehui http://orcid.org/0000-0003-0215-6095
Cheng, Qiang http://orcid.org/0000-0002-5213-5084
Chatterjee, Sumanta
Traylor, Zachary
Johnson, Lindsay T. http://orcid.org/0000-0002-4563-5486
Coquelin, Melissa L.
Wang, Jialu
Torres, Michael J.
Lian, Xizhen
Wang, Xu http://orcid.org/0000-0002-8925-5645
Xiao, Yufen http://orcid.org/0000-0002-5604-7479
Hodges, Craig A.
Siegwart, Daniel J. http://orcid.org/0000-0003-3823-1931
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA142543)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01 EB025192-01A1)
Cystic Fibrosis Foundation (SIEGWA18XX0, HODGES19R1)
Cancer Prevention and Research Institute of Texas (RP160157)
Article History
Received: 25 April 2023
Accepted: 27 October 2023
First Online: 11 November 2023
Competing interests
: A provisional patent application covering compositions, methods, and uses for targeting cystic fibrosis and related disorders has been filed by UT Southwestern naming T.W., Y.S., Q.C. and D.J.S as inventors. D.J.S. discloses financial interests in Signify Bio, ReCode Therapeutics, and Tome Biosciences. D.J.S. is a co-founder and member of the scientific advisory board of ReCode Therapeutics, which has licensed intellectual property from UT Southwestern. The remaining authors declare no competing interests.